The European Medicines Agency (EMA) has published guidance on classifying variations for veterinary medicinal products under Article 62 of Regulation (EU) 2019/6, outlining which post-authorisation changes require assessment and specifying the documentation to be submitted. The document, released on 28 April 2026, aims to harmonise procedures across EU member states and support the implementation of the new Veterinary Regulation, replacing previous guidelines under Directive 2001/82/EC.
Document scope and type The guidance is a non-binding recommendation intended to assist marketing authorisation holders and national competent authorities in interpreting the requirements of Article 62. It categorises variations into types – administrative, quality, safety, and efficacy – and provides detailed submission requirements for each. The document does not set new legal obligations but clarifies existing ones under Regulation (EU) 2019/6.
Policy orientations and trade-offs The guidance seeks to balance regulatory harmonisation with flexibility for industry. By providing clear classification criteria, it reduces uncertainty for veterinary pharmaceutical companies when submitting post-authorisation changes. However, the detailed documentation requirements may increase administrative burden for smaller firms, potentially raising compliance costs. The EMA emphasises that the guidance should facilitate consistent evaluation across member states, reducing divergent national interpretations that previously led to delays.
Impact on stakeholders - Veterinary pharmaceutical companies: Benefit from clearer rules on which variations need prior approval, reducing the risk of non-compliance. However, the detailed documentation requirements may increase submission preparation time and costs, particularly for small and medium-sized enterprises. - National competent authorities: Gain a harmonised framework for assessing variations, which should streamline review processes and reduce inconsistencies between member states. - Marketing authorisation holders: Must adapt their post-authorisation change management procedures to align with the new classification system, potentially requiring updates to internal quality systems. - Animal health sector: Ultimately benefits from more predictable regulatory pathways, which may encourage innovation and faster access to updated veterinary medicines.
Expected institutional follow-up The EMA will monitor implementation of the guidance and may update it based on feedback from stakeholders and national authorities. The European Commission is expected to adopt complementary implementing acts under Regulation (EU) 2019/6 to further detail variation procedures. The guidance is part of a broader transition to the new Veterinary Regulation, which fully applies from January 2022.
← Atlas › News › Health & Lifestyle